# US 2003/0232883 A1 · N-acylamino benzyl ether derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0232883 A1
- Document ID: US20030232883A1
- Status: Published application
- Kind: A1
- Application number: 10/445,580
- Filed: 2003-05-27
- Published: 2003-12-18
- Earliest claimed: 2002-05-29
- Assignees: Hoffman-La Roche Inc.
- Inventors: Synese Jolidon; Rosa Maria Rodriguez Sarmiento; Andrew William Thomas; Rene Wyler
- Web page: https://patentgrep.com/patent/US20030232883A1

## CPC

- C07C 259/06: having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 233/15: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C 233/25: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07C 233/33: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C 233/60: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 235/16: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 237/04: the carbon skeleton being acyclic and saturated
- C07C 237/22: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated (peptides C07K)
- C07C 243/14: of a saturated carbon skeleton
- C07C 243/28: to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
- C07C 255/19: containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
- C07C 255/23: containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
- C07C 255/25: Aminoacetonitriles
- C07C 323/41: Y being a hydrogen or an acyclic carbon atom
- C07C 2601/02: with a three-membered ring
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to N-acylamino aryl derivatives of the formula 1 where R1, R21, R22, R23, R3, R4, R5 R6, R7, R8, R, and n are as defined herein and where X is —CHRO, —OCHR—, —CH2S—, —SCH2—, —CH2CH2—, —CH═CH— or —C≡C—. The compounds of the invention are selective monoamine oxidase B inhibitors, and they are therefore useful in the treatment of diseases mediated by monoamine oxidase B, for example, for the treatment of Alzheimer's disease or senile dementia.

## Claims

### Claim 1

A compound of the formula
13
wherein
R1 is halogen, halogen-(C1-C6)-alkyl, cyano, (C1-C6)-alkoxy or halogen-(C1-C6)-alkoxy;
R21, R22, R23 and R24 are each independently selected from the group consisting of hydrogen, (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, hydroxy, (C1-C6)-alkoxy or —CHO;
R3 is hydrogen or (C1-C3)-alkyl;
R4, R5 are each independently selected from the group consisting of hydrogen, (C1-C6)-alkyl, (C1-C6)-alkoxy or —COO(C1-C6)alkyl, or, alternatively, R4 and R5, together with the C-atom to which they are attached, for a (C3-C7)-cycloalkyl ring;
R6 is —CO—NR7R8, —COO(C1-C6)-alkyl, —CN, —N(R)2 or —NHC(O)R;
R7 and R8 are each independently selected from the group consisting of hydrogen, (C1-C6)-alkyl, NH2 or hydroxy;
R is hydrogen or (C1-C6)-alkyl;
n is 0, 1, 2 or 3;
X is —CHRO, —OCHR—, —CH2S—, —SCH2—, —CH2CH2—, —CH═CH— or —C≡C—;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A Compound of claim 1 having the formula
14
wherein
R1 is halogen, halogen-(C1-C6)-alkyl, cyano,
(C1-C6)-alkoxy or halogen-(C1-C6)-alkoxy;
R21, R22, R23 and R24 are each independently selected from the group consisting of hydrogen and halogen;
R3 is hydrogen or (C1-C3)-alkyl;
R4 is hydrogen or (C1-C6)-alkyl;
R5 is hydrogen or (C1-C6)-alkyl;
or, alternatively, R4 and R5, together with the carbon atom to which they are attached, form a (C3-C7)-cycloalkyl ring;
R6 is —CO—NR7R8, —COO(C1-C6)-alkyl, or —CN;
R7 and R8 are each independently hydrogen, methyl or ethyl; and n is 1, 2 or 3;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A compound of formula I according to claim 1, wherein X is CH2O or OCH2.

### Claim 4 (depends on 1)

A compound of formula I according to claim 1, wherein X is CH2O, R1 is fluorine or trifluoromethyl and R6 is —COOCH3.

### Claim 5 (depends on 4)

A compound of claim 4, which is selected from the group consisting of
N-[4-(3-fluoro-benzyloxy)-phenyl]-malonamic acid methyl ester,
N-[3-fluoro-4-(3-fluoro-benzyloxy)-phenyl]-malonamic acid methyl ester,
N-[4-(4-fluoro-benzyloxy)-phenyl]-malonamic acid methyl ester,
N-[2-fluoro-4-(3-fluoro-benzyloxy)-phenyl]-malonamic acid methyl ester,
N-[4-(2,4-difluoro-benzyloxy)-phenyl]-malonamic acid methyl ester,
N-[4-(2-fluoro-benzyloxy)-phenyl]-malonamic acid methyl ester,
N-[4-(2,4,5-trifluoro-benzyloxy)-phenyl]-malonamic acid methyl ester,
N-[2-fluoro-4-(4-fluoro-benzyloxy)-phenyl]-malonamic acid methyl ester,
N-[4-(3,5-bis-trifluoromethyl-benzyloxy)-2-fluoro-phenyl]-malonamic acid methyl ester,
N-[4-(3-fluoro-benzyloxy)-3-methyl-phenyl]-malonamic acid methyl ester and
N-[3-chloro-4-(3-fluoro-benzyloxy)-phenyl]-malonamic acid methyl ester.

### Claim 6 (depends on 1)

A compound of formula I according to claim 1, wherein X is CH2O and R6 is —CONH2.

### Claim 7 (depends on 6)

A compound of claim 6, which is selected from the group consisting of cyclopropane-1,1-dicarboxylic acid amide [4-(3-fluoro-benzyloxy)-phenyl]-amide,
N-[4-(3-fluoro-benzyloxy)-phenyl]-malonamide,
N-[4-(3-fluoro-benzyloxy)-phenyl]-2-methyl-malonamide,
N-[3-fluoro-4-(3-fluoro-benzyloxy)-phenyl]-malonamide,
N-[4-(4-fluoro-benzyloxy)-phenyl]-malonamide,
N-[4-(2,4-difluoro-benzyloxy)-phenyl]-malonamide,
N-[4-(2,4,5-trifluoro-benzyloxy)-phenyl]-malonamide,
N-[4-(2-fluoro-benzyloxy)-phenyl]-malonamide,
N-(4-benzyloxy-phenyl)-malonamide,
N-[4-(4-chloro-benzyloxy)-phenyl]-malonamide,
N-[4-(3-fluoro-benzyloxy)-2-hydroxy-phenyl]-malonamide,
N-[2-fluoro-4-(4-fluoro-benzyloxy)-phenyl]-malonamide,
N-[4-(3-fluoro-benzyloxy)-3-methyl-phenyl]-malonamide,
N-[3-chloro-4-(3-fluoro-benzyloxy)-phenyl]-malonamide, and
cyclopropane-1,1-dicarboxylic acid amide [2-fluoro-4-(4-fluoro-benzyloxy)-phenyl]-amide.

### Claim 8 (depends on 1)

A compound of formula I according to claim 1, wherein X is —OCH2— and R6 is —NHCOCH3 or —NHCOH.

### Claim 9 (depends on 8)

A compound of claim 8, which is selected from the group consisting of
2-Acetylamino-N-[2-fluoro-4-(4-fluoro-benzyloxy)-phenyl]-acetamide,
2-Acetylamino-N-[2-fluoro-4-(3-fluoro-benzyloxy)-phenyl]-acetamide,
N-[2-Fluoro-4-(4-fluoro-benzyloxy)-phenyl]-2-formylamino-acetamide, and
N-[2-Fluoro-4-(3-fluoro-benzyloxy)-phenyl]-2-formylamino-acetamide.

### Claim 10 (depends on 1)

A compound of formula I according to claim 1, wherein X is —OCH2— and R6 is —NH2.

### Claim 11 (depends on 9)

A compound of claim 9, which is
2-amino-N-[2-fluoro-4-(4-fluoro-benzyloxy)-phenyl]-acetamide.

### Claim 12 (depends on 1)

A compound of formula I according to claim 1, wherein X is —CH2CH2—, —CH═CH—, or —C∉C—.

### Claim 13 (depends on 1)

A compound of formula I according to claim 1, wherein X is —CH═CH— and R6 is —COOCH3 or —CONH2.

### Claim 14 (depends on 13)

A compound of claim 13, which is selected from the group consisting of
N-{4-[2-(4-fluoro-phenyl)-vinyl]-phenyl}-malonamic acid methyl ester,
N-{4-[2-(3-fluoro-phenyl)-vinyl]-phenyl}-malonamide,
N-{4-[2-(4-fluoro-phenyl)-vinyl]-phenyl}-malonamide, and
N-{4-[2-(3-fluoro-phenyl)-vinyl]-phenyl}-malonamic acid methyl ester.

### Claim 15 (depends on 1)

A compound of claim 1, which is selected from the group consisting of
N-[4-(3-Fluoro-benzyloxy)-phenyl]-2-methyl-malonamic acid methyl ester;
N-[4-(3-Fluoro-benzyloxy)-phenyl]-2-methoxy-malonamic acid methyl ester;
N-[4-(3-Fluoro-benzyloxy)-2-trifluoromethyl-phenyl]-malonamic acid methyl ester;
N-[4-(3-Fluoro-benzyloxy)-phenyl]-N-methyl-malonamic acid methyl ester;
N-[4-(4-Trifluoromethyl-benzyloxy)-phenyl]-malonamic acid methyl ester;
N-(4-Benzyloxy-phenyl)-malonamic acid methyl ester;
N-[2-Fluoro-4-(4-trifluoromethyl-benzyloxy)-phenyl]-malonamic acid methyl ester;
N-[2-Fluoro-4-(4-fluoro-benzyloxy)-phenyl]-malonamic acid ethyl ester;
N-[4-(3-Fluoro-benzyloxy)-3-formyl-phenyl]-malonamic acid methyl ester;
N-[4-(3-Fluoro-benzyloxy)-3-methoxy-phenyl]-malonamic acid methyl ester; and
N-[2-Fluoro-4-(4-fluoro-benzyloxy)-phenyl]-2,2-dimethyl-malonamic acid methyl ester.

### Claim 16 (depends on 1)

A compound of claim 1, which is selected from the group consisting of
N-[4-(3-Fluoro-phenoxymethyl)-phenyl]-malonamic acid methyl ester;
N-[4-(3-Fluoro-benzylsulfanyl)-phenyl]-malonamic acid methyl ester;
2-[4-(3-Fluoro-benzyloxy)-phenylcarbamoyl]-malonic acid dimethyl ester;
N-{4-[2-(4-Fluoro-phenyl)-vinyl]-phenyl}-malonamic acid methyl ester;
N-{4-[2-(3-Fluoro-phenyl)-vinyl]-phenyl}-malonamic acid methyl ester;
N-{4-[2-(4-Fluoro-phenyl)-ethyl]-phenyl}-malonamic acid methyl ester;
N-{4-[2-(3-Fluoro-phenyl)-ethyl]-phenyl}-malonamic acid methyl ester;
N-{4-[2-(4-Methoxy-phenyl)-vinyl]-phenyl}-malonamic acid methyl ester; and N-{4-[2-(4-Chloro-phenyl)-ethyl]-phenyl}-malonamic acid methyl ester.

### Claim 17 (depends on 1)

A compound of claim 1, which is selected from the group consisting of
N-[4-(3-Fluoro-benzyloxy)-phenyl]-2,2-dimethyl-malonamide;
N-[4-(4-Trifluoromethyl-benzyloxy)-phenyl]-malonamide;
N-[2-Fluoro-4-(3-fluoro-benzyloxy)-phenyl]-malonamide;
N-[2,5-Difluoro-4-(3-fluoro-benzyloxy)-phenyl]-malonamide;
N-[4-(3-Fluoro-benzyloxy)-phenyl]-N′-hydroxy-malonamide;
N-[4-(3,5-Bis-trifluoromethyl-benzyloxy)-2-fluoro-phenyl]-malonamide;
N-[2-Fluoro-4-(4-trifluoromethyl-benzyloxy)-phenyl]-malonamide;
N-[4-(3-Fluoro-benzyloxy)-3-methoxy-phenyl]-malonamide;
N-[4-(3-Fluoro-benzylsulfanyl)-phenyl]-malonamide;
N-{4-[1-(3-Fluoro-phenyl)-ethoxy]-phenyl}-malonamide;
N-[4-(3-Fluoro-phenoxymethyl)-phenyl]-malonamide;
2-Ethyl-N-[4-(3-fluoro-benzyloxy)-phenyl]-malonamide;
N-{4-[2-(4-Fluoro-phenyl)-vinyl]-phenyl}-malonamide;
N-{4-[2-(3-Fluoro-phenyl)-vinyl]-phenyl}-malonamide;
N-{4-[2-(4-Fluoro-phenyl)-ethyl]-phenyl}-malonamide; and
N-{4-[2-(4-Chloro-phenyl)-ethyl]-phenyl}-malonamide.

### Claim 18 (depends on 1)

A compound of claim 1, which is selected from the group consisting of
2-Cyano-N-[4-(3-fluoro-benzyloxy)-phenyl]-acetamide;
N-[4-(3-Fluoro-benzyloxy)-phenyl]-2-hydrazinocarbonyl-acetamide;
Cyclopropane-1,1-dicarboxylic acid amide [4-(3-fluoro-phenoxymethyl)-phenyl]-amide;
2-Amino-N-[2-fluoro-4-(4-fluoro-benzyloxy)-phenyl]-acetamide (1:1) hydrochloride;
(R)-2-Amino-N-[2-fluoro-4-(4-fluoro-benzyloxy)-phenyl]-propionamide;
2-Amino-N-[2-fluoro-4-(4-fluoro-benzyloxy)-phenyl]-propionamide;
1-[2-Fluoro-4-(4-fluoro-benzyloxy)-phenylcarbamoyl]-2S-methyl-propyl-ammonium chloride;
(R)-2-Acetylamino-N-[2-fluoro-4-(4-fluoro-benzyloxy)-phenyl]-propionamide;
(R)-N-[2-Fluoro-4-(4-fluoro-benzyloxy)-phenyl]-2-formylamino-propionamide;
2-Amino-N-[2-fluoro-4-(3-fluoro-benzyloxy)-phenyl]-acetamide hydrochloride (1:1);
2-Amino-N-[2-fluoro-4-(4-trifluoromethyl-benzyloxy)-phenyl]-acetamide (1:1) hydrochloride;
2-Amino-N-[4-(3,5-bis-trifluoromethyl-benzyloxy)-2-fluoro-phenyl]-acetamide (1:1) hydrochloride;
2-Acetylamino-N-[4-(3,5-bis-trifluoromethyl-benzyloxy)-2-fluoro-phenyl]-acetamide; and
2-Amino-N-[4-(3-fluoro-benzyloxy)-phenyl]-acetamide hydrochloride.

### Claim 19 (depends on 1)

A process for the manufacture of a compound of formula I according to claim 1, which process comprises
reacting a compound of formula
15
with a compound of formula
16
to obtain a compound of formula
17

### Claim 20 (depends on 19)

The process of claim 19, further comprising converting the compound of formula I to a pharmaceutically acceptable salt.

### Claim 21

A composition comprising one or more compounds of the formula
18
wherein
R1 is halogen, halogen-(C1-C6)-alkyl, cyano, (C1-C6)-alkoxy or halogen-(C1-C6)-alkoxy;
R21, R22, R23 and R24 are each independently selected from the group consisting of hydrogen, (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, hydroxy, (C1-C6)-alkoxy or —CHO;
R3 is hydrogen or (C1-C3)-alkyl;
R4, R5 are each independently selected from the group consisting of hydrogen, (C1-C6)-alkyl, (C1-C6)-alkoxy or —COO(C1-C6)alkyl;
Or, alternatively, R4 and R5, together with the carbon atom to which they are attached, form a (C3-C7)-cycloalkyl ring;
R6 is —CO—NR7R8, —COO(C1-C6)-alkyl, —CN, —NR2 or —NHC(O)R;
R7 and R8 are each independently selected from the group consisting of hydrogen, (C1-C6)-alkyl, NH2 or hydroxy;
R is hydrogen or (C1-C6)-alkyl;
n is 0, 1, 2 or 3;
X is —CHRO, —OCHR—, —CH2S—, —SCH2—, —CH2CH2—, —CH═CH— or —C≡C—;
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 21)

A composition of claim 21, comprising one or more compounds of the formula
19
wherein
R1 is halogen, halogen-(C1-C6)-alkyl, cyano,
(C1-C6)-alkoxy or halogen-(C1-C6)-alkoxy;
R21, R22, R23 and R24 each are independently selected from the group consisting of hydrogen and halogen;
R3 is hydrogen or (C1-C3)-alkyl;
R4 is hydrogen or (C1-C6)-alkyl;
R5 is hydrogen or (C1-C6)-alkyl;
or, alternatively, R4 and R5, together with the carbon atom to which they are attached, form a (C3-C7)-cycloalkyl ring;
R6 is —CO—NR7R8, —COO(C1-C6)-alkyl, or —CN;
R7 and R8 are each independently hydrogen, methyl or ethyl; and
n is 1, 2 or 3;
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 1)

A method of treating a disease mediated by a monoamine oxidase B comprising administering to a patient a therapeutically effective amount of a compound of claim 1.

### Claim 24 (depends on 23)

The method of claim 23, wherein the monoamine oxidase B mediated disease is Alzheimer's disease or senile dementia.
